We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+25.98%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
Cap. Flow
+$59.1M
Cap. Flow %
3.53%
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5

Top Buys

1
IRON icon
Disc Medicine
IRON
+$23.2M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$20.3M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.6M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$13.3M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Top Sells

1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.6M
2
PCVX icon
Vaxcyte
PCVX
+$11M
3
RNAM
Avidity Biosciences
RNAM
+$7.67M
4
COGT icon
Cogent Biosciences
COGT
+$7.55M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$6.46M

Sector Composition

1 Healthcare 99.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
51
Zymeworks
ZYME
$1.78B
– –
-610,000
Closed -$5.51M
VECT
52
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-1,352,199
Closed -$11.6M
NBRV
53
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-17,025
Closed -$29.7K
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2023 Portfolio in Review

As of Q2 2023, Frazier Life Sciences Management held 53 positions worth $1.67B, up 21% from $1.38B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management deployed $59.1M of net new capital in Q2 2023, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Disc Medicine: 655,000 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Vaxcyte, an estimated $11M trimmed.

  • Frazier Life Sciences Management's largest Q2 2023 buy was Disc Medicine: 655,000 shares worth $29.1M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q2 2023, an estimated $20.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $11M.
  • Frazier Life Sciences Management fully exited VectivBio Holding AG Ordinary Shares in Q2 2023, selling an estimated $11.6M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.67B portfolio in Q2 2023.
  • Frazier Life Sciences Management opened 4 new positions and closed 5 in Q2 2023.
  • Frazier Life Sciences Management's portfolio value rose 21% quarter-over-quarter to $1.67B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.